Foretinib

Search with Google Search with Bing

Information
Drug Name
Foretinib
Description
Entry(CIViC)
6
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung non-small cell carcinoma ROS1 CD74-ROS1 G2032R D Predictive Supports Sensitivity/Response Somatic 3 26372962 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 G2032R D Predictive Supports Sensitivity/Response Somatic 2 25688157 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 L2155S D Predictive Supports Resistance Somatic 3 25688157 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 L2026M D Predictive Supports Sensitivity/Response Somatic 2 25688157 Detail
lung non-small cell carcinoma ROS1 CD74-ROS1 G2101A D Predictive Supports Sensitivity/Response Somatic 2 25688157 Detail
papillary renal cell carcinoma MET MUTATION MET MUTATION B Predictive Supports Sensitivity/Response Rare Germline 3 23213094 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Preclinical study analyzing the efficacy of dual R... ROS1 ROS1 CD74-ROS1 G2032R Sensitivity true CIViC Evidence detail
Ba/F3 cells expressing CD74–ROS1 G2032R showed res... ROS1 ROS1 CD74-ROS1 G2032R Sensitivity true CIViC Evidence detail
The L2155S mutation in ROS1 was identified in the ... ROS1 ROS1 CD74-ROS1 L2155S Resitance or Non-Reponse true CIViC Evidence detail
Ba/F3 cells expressing CD74–ROS1 L2026M mutation s... ROS1 ROS1 CD74-ROS1 L2026M Sensitivity true CIViC Evidence detail
Ba/F3 cells expressing CD74–ROS1 G2101A showed res... ROS1 ROS1 CD74-ROS1 G2101A Sensitivity true CIViC Evidence detail
In a retrospective analysis of 74 patients with pa... MET MET MUTATION MET MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT00920192 Completed Phase 1 Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer August 12, 2009 March 24, 2015
NCT01138384 Completed Phase 1/Phase 2 Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer October 27, 2010 February 13, 2015
NCT01147484 Completed Phase 2 A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer September 2, 2010 February 13, 2015
NCT02034097 Withdrawn Phase 2 A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer April 2014 December 2016